Exelixis Inc - EXEL Income before deduction of interest, taxes and amortization

Graphic logo of exelixis.com (EXEL)

Exelixis, Inc. (EXEL) operates on a high-scalability model where colossal development costs are followed by low-cost drug production. The absolute operating profit figures provided by GURU.Markets demonstrate financial stability, while the 1038.78 indicator reflects current dynamics. The company is implementing AI and robotics to accelerate drug design, yet reliance on Cabometyx sales and patents creates significant risks.

Exelixis Corp - EXEL Operating profit EBITDA (period 11/23/2025 - 11/10/2026)

Exelixis (EXEL) - metric breakdowns and financial figures

- market value and analyst target forecast:
Market Price Exelixis Inc.|EXEL - Consensus Target
- issuer market value details:
Market Value Exelixis|EXEL - Real Price to Acquire Entire Company
- book capitalization information:
Book Price of a Share Exelixis|EXEL - Book Capitalization|Market Capitalization to Book Value Ratio exelixis.com|EXEL - Aggregate Company Assets
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio Exelixis, Inc.|EXEL - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Exelixis Inc|EXEL - Company Aggregate Debts|Debts to Book Value Exelixis|EXEL - Company Long-Term Liabilities|Amount of Current Liabilities Exelixis|Immediate Liquidity exelixis.com
- financial results and valuation multiples details:
EXEL - Net Profit|Net Profit Forecast Exelixis, Inc.|EXEL - Price to Earnings Ratio|Future Price to Earnings Multiple exelixis.com|EXEL - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Exelixis|EXEL - Operating profit EBITDA|Earnings per share for the trailing year Exelixis|EXEL - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months exelixis.com|EXEL - Earnings per share growth in current year|Expected earnings per share trend next year Exelixis, Inc.
Summary company analytics:Exelixis, Inc.
Brand item of Exelixis

To find a fundamental floor, it is critical for an investor to assess the business's real liquidity. Michael Morrissey has effectively transformed Exelixis, Inc. (EXEL) into a profitable mechanism by monetizing oncology drugs. This EBITDA chart measures the daily cash flow from core operations. The metric excludes non-cash expenses, exposing true operational efficiency. The stability of this indicator confirms the asset's high reliability.

Competitor analysis for Exelixis, Inc.

Genmab Corp (GMAB) - Profit before interest, taxes and amortization|NUVL: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization KYMR (kymeratx.com)|IDYA (IDEAYA Biosciences, Inc.) - Operating profit before deduction of amortization|ELVN: Company profit before taxes, interest and amortization|ORIC (ORIC Pharma) - Operating profit EBITDA|Operating profit EBITDA Relay Corp|Profit before payment of interest, taxes and amortization Nurix Therapeutics (NRIX)|TYRA (tyra.bio) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA VSTM (Verastem)|Operating profit before depreciation charges Monte Rosa Therapeutics Inc|Cullinan Therapeutics Inc - Operating profit EBITDA|Profit before interest, taxes and amortization Immuneering Corp.|CCCC (C4 Therapeutics, Inc.) - Operating profit before deduction of amortization|BDTX: Company profit before taxes, interest and amortization|RPTX (Repare Therapeutics Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization PMV Pharmaceuticals Inc. PMVP|Operating profit EBITDA KPTI|propanc.com - Operating profit before amortization|Bio Green Med Solution Inc - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization AADI|ALRN: Operating profit before deduction of amortization|Blueprint Medicines - Company profit before taxes, interest and amortization|GLYC: Operating profit EBITDA|SpringWorks Therapeutics, Inc - Income before deduction of interest, taxes and amortization